1 / 33

ID Case Conference April 9, 2008

ID Case Conference April 9, 2008. Gretchen Shaughnessy, MD Clinical Fellow Dept of Infectious Diseases. CC: SOB.

yaron
Télécharger la présentation

ID Case Conference April 9, 2008

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. ID Case Conference April 9, 2008 Gretchen Shaughnessy, MD Clinical Fellow Dept of Infectious Diseases

  2. CC: SOB • 46M presented to PCP with SOB and cough productive of white sputum. No hemoptysis, cough had been progressive over the past 3 weeks. He had been on Biaxin x 10 days without improvement. He’d also noticed some orthopnea, but denied any post-nocturnal dyspnea. Over the past 4-6 weeks he reported a 20lb wt loss and intermittent night sweats. Admitted to Outside Hospital for further workup.

  3. HPI • During admission to Outside Hospital the patient had a normal echo (no pulm HTN), chest CT with moderate R pleural effusion and LLL interstitial process. • Sputum cultures and pleural fluid analysis and cultures were done. • Bronchoscopy with biopsy done day 6 of hospitalization, complicated by tension pneumothorax requiring chest tube placement. • Despite broad specturm antibiotics and chest tube placement his respiratory status declined from 11/14-11/23. Transferred to UNC MICU.

  4. PMH • HTN • DM – type II • GERD • Hiatial Hernia • Hyperlipidemia • h/o R shoulder surgery in 2001 • CRI – baseline Cr 1.6

  5. Medications • Allergies – NKDA • Atenolol 100mg daily • Nexium 40mg daily • Glyburide 5mg po BID

  6. Antibiotic History • 11/4-11/14 Biaxin • 11/14-11/23 Azithromycin & Ticaricillin/clavulanate • 11/21-11/23 Methylpredisolone 60mg IV q8h

  7. Social History • No tob, ETOH, or drugs. • Currently works in construction, former truck driver. A few weeks ago was sweeping parking lots and exposed to a lot of dust. • No recent sick contacts. • No recent travel. • Frequently rides in a friend’s van that is used to transport chickens and rabbits (patient has never encountered the animals in person) • History of travel to the southwest as a truck driver, but none in the past 2 years. • Denies HIV risk factors, has never been tested.

  8. Family History • Mother - DM type II • Father – ETOH induced liver disease • No family history of autoimmune disease • Patient’s mother had Mycobacterial Tuberculosis 15 years ago. He reports 6 months of treatment for his mother and the whole family had to get PPDs placed. The patient’s PPD was positive but he does not remember getting LTBI treatment.

  9. ROS • Night sweats and weight loss for 6 weeks • No chest pain, no N/V/D, no BRBPR, no hematuria or dysuria. • No joint pain or swelling. • No rashes or skin lesions. • Otherwise negative ROS.

  10. T 37.7 - HR 110 - RR 36 - BP 95/65 – 99% on 100% NRB Tachypnec, on 100% NRB a&ox3, pleasant and cooperative mild errythema seen on the ventral surface of the elbow on the RUE soft NT nabs, no HSM no c/c/e nl tone, full ROM present no focal defecits EOMI, PERRLA, nonicteric no e/e on OP no JVD no LAD appreciated in cervical, supraclavicular, or inguinal regions II/VI systolic murmur decreased breath sounds at the bases. L chest wall is higher than R, crepitus present. chest tube present Physical Exam

  11. OSH Labs • Pleural fluid - exudative process, pH was 8 and the glucose was reportedly elevated • Micro from bronch- gram stain many WBCs, yeast, rare GPCs. • aerobic cultures candida albicans only • anaerobic cultures no growth • fungal cultures growing candida albicans only • AFB smear and culture pending at the state lab. • Bronch biopsy – diffuse fibrosis and inflammation, ?UIP

  12. OSH Labs • Urine microscopy: granular casts, monomorphic red cells, and yeast with pseudohyphae • urine microalbumin 100 (11/24), UP/C 4.069 • UA 1.010/5.0/1+ protein/3+ blood/7 WBC/148 RBC/4 granular casts/occ bacteria • HgbA1C 8.2 • ESR 68 • SPEP and UPEP negative • ANA, ENA panel negative

  13. Radiology

  14. Discussion

  15. Labs • Serum crypto, urine histo, urine legionella negative • PCP DFA negative from bronch • AFB smears and cultures from bronch, pleural fluid, all negative

  16. Further Hospital Course • Patient had slides from lung biopsy sent to UNC • Pathology showed findings concerning for acute interstitial fibrosis. AFB, bacterial, viral, and fungal cultures all negative. • Hypoxia progressed, ARDS, unable to oxygenate • Patient expired on post-transfer day #10

  17. “A Diagnostic test was performed…” • Unfortunately, autopsy. (“Pathologists always get the diagnosis… just a little late.”) • Late exudative stage of early organizing stage idiopathic diffuse alveolar damage (acute interstitial pneumonia). • Severe bilateral acute interstitial pneumonia • Nephrotic range proteinuria 2/2 minimal change disease • All cultures and microscopic analysis negative • Diagnosis – Hamman Rich Syndrome

  18. Hamman-Rich Syndrome • Acute interstitial pneumonia • Described by Hamman and Rich in 1934 • Rare and fulminant form of rapidly fibrosing lung disease (idiopathic DAD) • Occurs in previously healthy individuals without a history of lung disease, presents within days to weeks of onset of symptoms • Unknown mechanism of the damage to the pulmonary endothelium and epithelium

  19. Hamman-Rich Syndrome • Onset usually abrupt, prodromal illness lasts 7 to 14 days • Most common clinical signs and symptoms are fever, cough, and shortness of breath • Not associated with cigarette smoking • Most patients are over the age of 40 years, with a mean age of 50 to 55 years

  20. Treatment • Prognosis is poor, mortality rate >60% at initial presentation. • Most patients die within 6 months • Treatment is supportive, attempt to identify any possible cause

  21. References • Mandell’s Principles and Practices of Infectious Disease, 6th Ed. • Hamman, L, Rich, AR. Fulminating diffuse interstitial fibrosis of the lungs. Trans Am Clin Climatol Assoc 1935; 51:154. • Vourlekis, JS. Acute interstitial pneumonia. Clin Chest Med 2004; 25:739. • Katzenstein, ALA, Myers, JL, Mazur, MT. Acute interstitial pneumonia. A clinicopathologic, ultrastructural, and cell kinetic study. Am J Surg Pathol 1986; 10:256. • Bouros, D, Nicholson, AC, Polychronopoulos, V, du Bois, RM. Acute interstitial pneumonia. Eur Respir J 2000; 15:412.6.Vourlekis, JS, Brown, KK, Cool, CD, et al. Acute interstitial pneumonitis. Case series and review of the literature. Medicine (Baltimore) 2000; 79:369. • Fulmer, JD, Katzenstein, ALA. The interstitial lung diseases. In: Pulmonary and Critical Care Medicine, Bone, RC (Ed), Mosby Year Book, St. Louis; 1993, M1.8.Olson, J, Colby, TV, Elliott, CG. Hamman-Rich syndrome revisited. Mayo Clin Proc 1990; 65:1538. • Primack, SL, Hartman, TE, Ikezoe, J, et al. Acute interstitial pneumonia: Radiographic and CT findings in nine patients. Radiology 1993; 188:817. • Johkoh, T, Muller, NL, Taniguchi, H, et al. Acute interstitial pneumonia: Thin-section CT findings in 36 patients. Radiology 1999; 211:859.

More Related